Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSQQ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,190
Award facts
- Contract value 100% obligated
- $15,189.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $15,189.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL syringes. The delivery order, issued on December 22, 2025, with an ultimate completion date of January 14, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendors to support the Department of Defense's recurring pharmaceutical and medical supply needs.
DMS Pharmaceutical Group leverages its established position as a critical supplier within the federal pharmaceutical supply chain, having been registered in the System for Award Management since 2001. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables delivered to military healthcare facilities. The PPV-G GEN V contract, awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, positions DMS Pharmaceutical Group to fulfill the diverse and specialized pharmaceutical requirements of the Department of Defense healthcare operations globally throughout a 30-month base period with three optional 30-month renewal periods.
Quick answers
Who was awarded contract SPE2DR26FSQQ5?
SPE2DR26FSQQ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FSQQ5 worth?
The government has obligated $15,190 on SPE2DR26FSQQ5.
Is contract SPE2DR26FSQQ5 an order under another contract?
Yes. SPE2DR26FSQQ5 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQQ5 competed?
The extent of competition for SPE2DR26FSQQ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award